A Phase II Study of Antibody-Drug Conjugates (ADCs) Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
Latest Information Update: 03 Jun 2024
Price :
$35 *
At a glance
- Drugs Adebrelimab (Primary) ; SHR-A1921 (Primary) ; Trastuzumab rezetecan (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 03 Jun 2024 New trial record